Takara Bio Inc
TF2
Company Profile
Business description
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
Contact
Nojihigashi 7-4-38 Kusatu
Shiga
Otsu520-0058
JPNT: +81 775656920
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
1,779
Stocks News & Analysis
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,591.20 | 64.10 | -0.74% |
| CAC 40 | 7,701.95 | 67.36 | -0.87% |
| DAX 40 | 22,300.75 | 312.22 | -1.38% |
| Dow JONES (US) | 45,165.80 | 794.31 | -1.73% |
| FTSE 100 | 9,967.35 | 4.82 | -0.05% |
| HKSE | 24,951.88 | 95.45 | 0.38% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 50,924.74 | 2,448.33 | -4.59% |
| NZX 50 Index | 12,716.86 | 218.53 | -1.69% |
| S&P 500 | 6,370.69 | 106.47 | -1.64% |
| S&P/ASX 200 | 8,395.20 | 65.70 | -0.78% |
| SSE Composite Index | 3,913.72 | 0.00 | 0.00% |